Prices delayed by 15 minutes
Next earnings report: none scheduled in the next five weeks · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Zoetis Inc. trades on NYSE under the ticker ZTS. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks ZTS has traded between 68.77 $ and 148.30 $. As of 09 October 2026 the price stood 5.42 % of the way from the 52-week low to the high.
Over one year ZTS shares fell 48.81 %; over six months they fell 39.09 %. Volatility over 90 days is 30.47 %. Dividends are not included: this is price change only, as of 09 October 2026.
ZTS trades at a price-to-earnings ratio of 11.6, below the sector median of 24.8. Price to sales is 3.2, below the sector median of 3.9. Price to book is 9.5, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 71.36 | 73.75 | 71.15 | 73.08 | 6M |
| 07 October 2026 | 71.73 | 72.09 | 71.12 | 71.55 | 4M |
| 06 October 2026 | 71.88 | 72.30 | 70.59 | 71.33 | 3M |
| 05 October 2026 | 69.41 | 71.47 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Zoetis makes medicines and vaccines for animals — from household pets to commercial herds.
The veterinary market is gentler than the human one: no insurers dictate price, patent expiries pass without a collapse, and products stay on the market for decades. The owner pays out of pocket and does so willingly — spending on pet health grew faster than consumer spending generally for decades.
The most valuable products treat chronic conditions such as dermatitis and osteoarthritis, which put the animal on a lifelong course and give the company recurring revenue. The other half, livestock medicine, depends on meat and milk prices and is markedly more cyclical. Risks: generic competition and the discretionary nature of pet spending in a downturn. Zoetis pays a dividend.
Address:10 SYLVAN WAY, PARSIPPANY, NJ, 07054, US
Zoetis Inc. reported revenue of 9.5B $ and net income of 2.6B $ over the last four quarters. Net margin is 27.79 %. Revenue changed by +2.40 % year over year. Earnings per share are 6.03 $. Market capitalisation is 30.8B $.
ZTS has a return on equity of 81.75 %, above the sector median of −41.68 %. Return on assets is 17.44 %, above the sector median of −32.11 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 69.00 |
| 71.41 |
| 4M |
| 02 October 2026 | 69.12 | 70.10 | 68.77 | 69.69 | 5M |
| 01 October 2026 | 70.00 | 70.90 | 68.92 | 69.10 | 5M |
| 30 September 2026 | 70.55 | 70.77 | 69.52 | 69.83 | 4M |
| 29 September 2026 | 71.40 | 71.70 | 70.00 | 70.30 | 4M |
| 28 September 2026 | 70.50 | 71.68 | 70.08 | 71.43 | 4M |
| 25 September 2026 | 70.00 | 71.08 | 69.52 | 71.05 | 4M |
| 24 September 2026 | 71.85 | 72.38 | 69.93 | 70.27 | 3M |
| 23 September 2026 | 72.75 | 73.55 | 71.55 | 71.61 | 4M |
| 22 September 2026 | 71.98 | 73.46 | 71.24 | 72.86 | 4M |
| 21 September 2026 | 72.06 | 72.48 | 70.26 | 71.33 | 4M |
| 18 September 2026 | 72.57 | 73.05 | 71.40 | 71.40 | 10M |
| 17 September 2026 | 73.35 | 73.45 | 72.00 | 73.02 | 4M |
| 16 September 2026 | 73.47 | 73.90 | 72.92 | 73.00 | 5M |
| 15 September 2026 | 72.91 | 73.78 | 72.72 | 73.43 | 4M |
| 14 September 2026 | 74.20 | 74.82 | 73.49 | 73.67 | 4M |
| 11 September 2026 | 73.24 | 73.50 | 71.50 | 72.97 | 5M |